Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment
- 1 February 2002
- journal article
- clinical trial
- Published by Elsevier in Thrombosis Research
- Vol. 105 (3) , 225-231
- https://doi.org/10.1016/s0049-3848(02)00031-2
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- The Pharmacokinetics of Subcutaneous Enoxaparin in End‐Stage Renal DiseasePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2001
- Enoxaparin Prevents Death and Cardiac Ischemic Events in Unstable Angina/Non–Q-Wave Myocardial InfarctionCirculation, 1999
- EnoxaparinDrugs, 1998
- A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery DiseaseNew England Journal of Medicine, 1997
- EnoxaparinDrugs, 1995
- EnoxaparinDrugs, 1992
- Delayed elimination of enoxaparine in patients with chronic renal insufficiencyThrombosis Research, 1991
- Pharmacokinetics and biodistribution of technetium 99m labelled standard heparin and a low molecular weight heparin (enoxaparin) after intravenous injection in normal volunteersBritish Journal of Haematology, 1991
- Pharmacotherapeutic Aspects of Unfractionated and Low Molecular Weight HeparinsDrugs, 1990
- Heparin half‐life in normal and impaired renal functionClinical Pharmacology & Therapeutics, 1974